Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 97 of 1923 for:    "bone marrow" | Recruiting, Not yet recruiting Studies

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for OA (RMIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04815902
Recruitment Status : Not yet recruiting
First Posted : March 25, 2021
Last Update Posted : March 25, 2021
Sponsor:
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by (Responsible Party):
Steadman Philippon Research Institute

Brief Summary:
This is a prospective, randomized, double-blind, active control clinical trial to evaluate the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, to improve beneficial effect demonstrated by the active control which is to be injection of autologous bone marrow aspirate concentrate (BMAC) into an osteoarthritic knee.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: Fisetin Drug: Losartan Drug: Placebo - Losartan Drug: Placebo Fisetin Phase 1 Phase 2

Detailed Description:
This is a prospective, randomized, double-blind, active control clinical trial to evaluate the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, to improve beneficial effect demonstrated by the active control which is to be injection of autologous bone marrow aspirate concentrate (BMAC) into an osteoarthritic knee. 100 subjects with symptomatic unilateral or bilateral knee osteoarthritis (Kellgren-Lawrence grade II-IV) will be randomized into one of four arms (1:1:1:1). All subjects will receive an injection of BMAC. Group 1-n=25: Control (BMA concentrate + Fisetin Placebo + Losartan Placebo) Group 2-n=25: BMA concentrate + Fisetin Placebo + Active Losartan Group 3-n=25: BMA concentrate + Active Fisetin + Losartan Placebo Group 4-n=25: BMA concentrate + Active Fisetin + Active Losartan

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Estimated Study Start Date : April 1, 2021
Estimated Primary Completion Date : October 30, 2024
Estimated Study Completion Date : April 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Active Fisetin and Active Losartan
Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
Drug: Fisetin
Oral Fisetin 20 mg/kg taken for 10 days total.
Other Names:
  • Novusetin
  • 7,3',4'-flavon-3-ol
  • 3,3',4',7-tetrahydroxyflavone

Drug: Losartan
12.5 mg oral Losartan taken for 30 days total.
Other Name: Losartan potassium

Active Comparator: Active Fisetin and Losartan Placebo
Losartan Placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
Drug: Fisetin
Oral Fisetin 20 mg/kg taken for 10 days total.
Other Names:
  • Novusetin
  • 7,3',4'-flavon-3-ol
  • 3,3',4',7-tetrahydroxyflavone

Drug: Placebo - Losartan
Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
Other Name: Placebo Oral Capsule

Active Comparator: Fisetin Placebo and Active Losartan
Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
Drug: Losartan
12.5 mg oral Losartan taken for 30 days total.
Other Name: Losartan potassium

Drug: Placebo Fisetin
Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
Other Name: Placebo Oral Capsule

Placebo Comparator: Control
Losartan placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
Drug: Placebo - Losartan
Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
Other Name: Placebo Oral Capsule

Drug: Placebo Fisetin
Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
Other Name: Placebo Oral Capsule




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: Adverse events will be collected from the date of BMAC injection to 12 months after injection ]
    Occurrence of adverse events


Secondary Outcome Measures :
  1. Morphological and Quantitative Magnetic Resonance Imaging (MRI) [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection) ]
    Cartilage quality assessed by blinded radiologist using morphological MRI. Quantitative MRI using T2 mapping images with texture analysis used to assess water content and collagen organization within the cartilage and surrounding tissue

  2. Evaluation of patient reported outcome (PRO) for quality of life [ Time Frame: within 3 months of injection, 32 days post baseline, 14 days post injection, 30 days post injection, 3 months post injection, 6 months post injection, 12 months post injection, 18 months post injection ]
    12-question Short-Form General Health Survey (SF-12) - Including Physical Component Summary (PCS) and Mental Component Summary (MCS).

  3. Evaluation of patient reported outcome (PRO) for knee functions (WOMAC) [ Time Frame: within 3 months of injection, 32 days post baseline, 14 days post injection, 30 days post injection, 3 months post injection, 6 months post injection, 12 months post injection, 18 months post injection ]
    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (24 questions; rated none, mild, moderate, or severe. Higher WOMAC score represents higher disability)

  4. Evaluation of patient reported outcome (PRO) for knee functions (Tegner) [ Time Frame: within 3 months of injection, 32 days post baseline, 14 days post injection, 30 days post injection, 3 months post injection, 6 months post injection, 12 months post injection, 18 months post injection ]
    Tegner Physical Activity Scale (1 question; scale of 0 to10; 0 representing a low activity level and 10 representing a high activity level)

  5. Evaluation of patient reported outcome (PRO) for knee functions (IKDC) [ Time Frame: within 3 months of injection, 32 days post baseline, 14 days post injection, 30 days post injection, 3 months post injection, 6 months post injection, 12 months post injection, 18 months post injection ]
    International Knee Documentation Committee (IKDC) Form. (scores range from 0 points or lowest level of function, to 100 points or highest level of function)

  6. Patient-Reported Outcome Questionnaires [ Time Frame: Screening, weekly post 1st study drug dose (pre-injection), weekly post injection (for 4 months) ]
    Numerical Rating Scale (NRS) for knee pain (6 questions with a scale of 0 to 10; 0 representing no pain and 10 representing extreme pain)

  7. Change in muscle strength of the study knee [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection ]
    Isokinetic Dynamometry

  8. Change in physical function of the Study Knee (LEK) [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection ]
    Lower Extremity Kinematics

  9. Change in physical function of the Study Knee (Stair Test) [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection] ]
    Stair Test

  10. Change in physical function of the Study Knee (fast 40-meter walk) [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection ]
    Fast 40-meter walk

  11. Change in physical function of the Study Knee (TUG) [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection ]
    Timed up-and-go test

  12. Change in physical function of the Study Knee (6-minute walk test) [ Time Frame: 32 days prior to injection, 6 months post injection, 12 months post injection] ]
    6-minute walk test

  13. Change in associate biomarkers as compared to placebo in peripheral blood plasma/serum [ Time Frame: screening, 14 days post-injection, 30 days post injection, 3 months post injection, 6 months post injection, 12 months post injection ]
    Immunoassays for Biomarker assessment from blood serum. Analytes will be measured via immunoassays. The following analytes will be measured and reported in pg/ml. IL-1b, IL-6, IL-15, IL-1a, IL-1Ra, IL-7, IL-8, MCP-1, TNF-a , RANTES, VEGF, IFN-g, GRO, IP10, Eotaxin, PDGF-AA, PDGFAB-BB, EGF, FLT3L, GDF15, GDF11, FGF21, IL-18, SOST, OC, FGF-23, PTH, Leptin, Insulin, TIMP1, TIMP2, TGF-b1, TGF-b2, MMP-1, MMP-2, MMP-9, MMP-10, HA, COMP, CS846, CRP.

  14. Change in CTX-II as compared to placebo in urine [ Time Frame: 32 days post baseline , 6 months post injection, 12 months post injection ]
    Immunoassays for CTX-II detection in urine reported as pg/ml

  15. Change in levels of senescent PBMCS (total and specific PBMC subsets such as T-Cells) [ Time Frame: screening, 14 days post-injection, 30 days post injection, 3 months post injection, 6 months post injection, 12 months post injection ]
    Flow Cytometry based detection and quantification of senescent PBMCs isolated from whole blood. Intensity of the fluorescent marker C12FDG will be measured. Cells positive for C12FDG will be quantified and designated as senescent.

  16. Change in synovial fluid content [ Time Frame: 32 days post baseline , 6 months post injection, 12 months post injection ]
    Synovial Fluid Analysis

  17. Characterization of Bone Marrow Derived Aspirate Concentrate cell content prior to injection [ Time Frame: 32 days post baseline ]
    BMAC Analysis

  18. Characterization of Bone Marrow Derived plasma biomarkers prior to injection [ Time Frame: 32 days post baseline ]
    BMAC Analysis

  19. Change in time to conversion to alternative treatment [ Time Frame: Subjects may receive alternative treatment at any point during the 18-month study, continued participation will be determined on an individual basis (The time to resort to alternative therapy from baseline will be recorded) ]
    Alternative procedure as indicated. The time to resort to alternative therapy from baseline will be recorded



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capacity to personally give informed consent (consent via legally authorized representative will not be accepted) and who are willing to comply with all study-related procedures and assessments;
  2. Between 40 and 85 years of age;
  3. Ambulatory persons with osteoarthritis (OA) of at least one knee (Kellgren-Lawrence grade II-IV);
  4. Mean baseline pain of 3-10 points on the target knee and a pain differential of at least -2 points on the contralateral knee as exhibited by 24-hour mean pain score (on the 11-point Numeric Rating Scale) for at least five of the seven days during the baseline period.

Exclusion Criteria:

Previous or Planned Knee Surgeries, Procedures and/or Treatments:

  1. Planned surgery on either the contralateral or target knee at any time during the Study period including dosing and follow-up;
  2. Within 6 months of signing informed consent has received diagnostic arthroscopy of the target knee or arthroscopic surgery (including microfracture and meniscectomy) on the target knee;
  3. Within 12 weeks of signing informed consent has received intra-articular treatment of the target knee with steroids or hyaluronic acid derivatives;
  4. History of previous total or partial arthroplasty in the target knee. Partial or total arthroplasty in the contralateral knee is acceptable as long as the surgery was performed at least 6 months prior to enrollment and the operative knee is asymptomatic;

    Current and/or Previous Medical Conditions, Surgeries and/or Procedures:

  5. Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of subjects with a history of treated basal or squamous cell carcinoma);
  6. Current diagnosis of fibromyalgia based on ACR criteria;
  7. History of diabetes mellitus according to the American Diabetes Association criteria, or subjects previously diagnosed by a qualified physician as having diabetes (American Diabetes Association Standards of Medical Care in Diabetes 2016);
  8. Any active known or suspected systemic autoimmune disease (except for vitiligo, residual auto-immune hypothyroidism requiring hormone replacement only, psoriasis not requiring systemic treatment for two years, conditions not expected to recur in the absence of an external trigger) or any history of a systemic inflammatory arthritis such as psoriatic, rheumatoid, ankylosing spondylitis or reactive arthritis;
  9. Within 6 months of signing informed consent has undergone regenerative knee joint procedures including, but not limited to, platelet-rich plasma injections, mesenchymal stem cell transplantation, autologous chondrocyte transplantation, or mosaicplasty;
  10. Current or prior history of other joint diseases including but not limited to joint dysplasia, crystal-induced arthropathy (such as gout, or calcium pyrophosphate deposition disease evidenced by clinical and/or radiographic means), aseptic osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler syndrome, joint infection, hemochromatosis, or neuropathic arthropathy of any cause;
  11. Any medical condition, including findings in laboratory or medical history or in the baseline assessments, that (in the opinion of the Principal Investigator or his designee), constitutes a risk or contraindication for participation in the Study or that could interfere with the Study conduct, endpoint evaluation or prevent the subject from fully participating in all aspects of the Study;
  12. Females who nursing a child, are pregnant or planning to become pregnant during study drug dosing;
  13. Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during study drug dosing;
  14. Unable to safely undergo an MRI based on MRI safety screening (for example, due to incompatible device/implant, severe claustrophobia, BMI greater than 40 kg/m2, or size exceeding the limits of the of the MRI equipment (coil and gantry);

    Current and/or Previous Medications and Supplements:

  15. Taking medications that affect insulin activity, including Metformin or Acarbose within 1 week of signing informed consent;
  16. Currently taking Losartan or Fisetin, allergy to any active or inactive ingredient of Losartan or Fisetin, and/or currently taking medication with known Losartan or Fisetin interaction;
  17. Within 3 months of signing informed consent have taken senolytic agents including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
  18. Subjects with any of the following drug/medication statuses:

    1. Currently taking Losartan;
    2. Currently taking Warfarin or related anticoagulants;
    3. Currently taking Lithium;
    4. Opioid analgesics taken in the past 8 weeks and are not willing to discontinue these medications through the duration of the study;
    5. Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
    6. Drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, other chemotherapy drugs;
    7. Subjects taking the following other drugs if they cannot be held (per the Principal

    Investigator) for at least 2 days before and during administration of Fisetin:

    cyclosporine, tacrolimus, repaglinide, and bosentan.

  19. Taking a glucocorticoid within 1 month of signing informed consent;
  20. Within 8 weeks of signing informed consent has used opioid analgesics, and are not willing to discontinue these medications through the duration of the study;
  21. Within the 3 months of signing informed consent has received anticonvulsant therapy, pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal), calcium supplementation of > 1200 mg/d;
  22. Within the 12 months prior to signing informed consent received any medications that affect bone turnover, including: adrenocorticosteroids (> 3 months at any time or > 10 days, estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide;
  23. Inability to tolerate oral medication;
  24. Inadequate amount of BMA collected to serve the needs of the patient, ProofPoint Biologics and/or of the SPRI laboratory.

Behavioral Modification - Participants will be educated about the risk of excessive caffeine usage. Participants will be encouraged to reduce use by 50% prior to and during the Fisetin dosing days. Due to drug-drug interaction, subjects may not clear the caffeine from their system properly/as usual.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04815902


Contacts
Layout table for location contacts
Contact: Suzanne L Page, JD 970-401-8770 spage@sprivail.org
Contact: Michael Begg, PA 970-401-8755 mbegg@sprivail.org

Locations
Layout table for location information
United States, Colorado
The Steadman Clinic
Vail, Colorado, United States, 81657
Contact: Suzanne L Page, JD    970-401-8770    spage@sprivail.org   
Principal Investigator: Leslie B Vidal, MD         
Sponsors and Collaborators
Steadman Philippon Research Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Investigators
Layout table for investigator information
Principal Investigator: Leslie B Vidal, MD The Steadman Clinic
Layout table for additonal information
Responsible Party: Steadman Philippon Research Institute
ClinicalTrials.gov Identifier: NCT04815902    
Other Study ID Numbers: 2020-15
1UG3AR077748-01 ( U.S. NIH Grant/Contract )
First Posted: March 25, 2021    Key Record Dates
Last Update Posted: March 25, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Steadman Philippon Research Institute:
Fisetin
Losartan
Osteoarthritis
Knee
Bone Marrow Concentrate
Bone Marrow Aspirate
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Losartan
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action